Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
Meeting ReportOncology: Basic, Translational & Therapy

Radioimmunotherapy with 131I-L19SIP (Radretumab) in metastatic solid tumors: Preliminary results

Giorgio Virotta, Gian Luca Poli, Anna Bettini, Claudia Bianchi, Leonardo Giovannoni, Alberto Gerali, Antonello Quadri, Carlo Tondini and Andrea Bruno
Journal of Nuclear Medicine May 2012, 53 (supplement 1) 498;
Giorgio Virotta
1Nuclear Medicine, Ospedali Riuniti, Bergamo, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gian Luca Poli
2Health Physics, Ospedali Riuniti, Bergamo, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna Bettini
3Oncology, Ospedali Riuniti, Bergamo, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claudia Bianchi
2Health Physics, Ospedali Riuniti, Bergamo, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leonardo Giovannoni
4Clinical Research, Philogen SpA, Siena, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alberto Gerali
1Nuclear Medicine, Ospedali Riuniti, Bergamo, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antonello Quadri
3Oncology, Ospedali Riuniti, Bergamo, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carlo Tondini
3Oncology, Ospedali Riuniti, Bergamo, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrea Bruno
1Nuclear Medicine, Ospedali Riuniti, Bergamo, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Article Information

vol. 53 no. supplement 1 498

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Published online November 4, 2014.

Copyright & Usage 
© 2012

Author Information

  1. Giorgio Virotta1,
  2. Gian Luca Poli2,
  3. Anna Bettini3,
  4. Claudia Bianchi2,
  5. Leonardo Giovannoni4,
  6. Alberto Gerali1,
  7. Antonello Quadri3,
  8. Carlo Tondini3 and
  9. Andrea Bruno1
  1. 1Nuclear Medicine, Ospedali Riuniti, Bergamo, Italy
  2. 2Health Physics, Ospedali Riuniti, Bergamo, Italy
  3. 3Oncology, Ospedali Riuniti, Bergamo, Italy
  4. 4Clinical Research, Philogen SpA, Siena, Italy

Statistics from Altmetric.com

Cited By...

  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

Article usage

Article usage: November 2014 to January 2023

AbstractFullPdf
Nov 2014100
Feb 2015100
Mar 2015200
Apr 2015200
Jun 2015700
Jul 2015400
Sep 2015600
Dec 2015100
Jan 2016100
Feb 2016300
Mar 2016500
Apr 2016500
May 2016100
Jun 2016600
Jul 2016900
Aug 2016700
Sep 20161200
Oct 20161200
Nov 2016500
Dec 2016200
Jan 2017500
Feb 20171100
Mar 2017200
Apr 2017500
May 2017200
Jun 2017200
Jul 2017500
Aug 2017400
Sep 2017600
Oct 2017400
Nov 2017400
Dec 2017200
Jan 2018100
Mar 2018200
Apr 2018500
May 2018200
Jun 2018200
Jul 2018200
Sep 2018400
Nov 2018300
Dec 2018300
Jan 2019100
Feb 2019100
Apr 20191800
May 2019100
Jun 20191300
Jul 2019200
Aug 2019500
Nov 2019500
Dec 2019600
Jan 2020100
Feb 2020700
Mar 20201800
Apr 20201400
May 2020300
Jun 2020300
Jul 2020400
Aug 20201400
Sep 20202300
Oct 20201000
Nov 20202000
Dec 20201100
Jan 2021500
Feb 20211200
Mar 20211400
Apr 20217400
May 20211300
Jun 20211700
Jul 20211800
Aug 20213500
Sep 20211500
Oct 20212400
Nov 20215800
Dec 20212800
Jan 20225400
Feb 20221900
Mar 20222200
Apr 20221100
May 20222300
Jun 2022800
Jul 2022500
Aug 2022700
Sep 2022100
Oct 20221000
Nov 2022400
Dec 2022100
Jan 2023900
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 53, Issue supplement 1
May 2012
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Radioimmunotherapy with 131I-L19SIP (Radretumab) in metastatic solid tumors: Preliminary results
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Radioimmunotherapy with 131I-L19SIP (Radretumab) in metastatic solid tumors: Preliminary results
Giorgio Virotta, Gian Luca Poli, Anna Bettini, Claudia Bianchi, Leonardo Giovannoni, Alberto Gerali, Antonello Quadri, Carlo Tondini, Andrea Bruno
Journal of Nuclear Medicine May 2012, 53 (supplement 1) 498;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Radioimmunotherapy with 131I-L19SIP (Radretumab) in metastatic solid tumors: Preliminary results
Giorgio Virotta, Gian Luca Poli, Anna Bettini, Claudia Bianchi, Leonardo Giovannoni, Alberto Gerali, Antonello Quadri, Carlo Tondini, Andrea Bruno
Journal of Nuclear Medicine May 2012, 53 (supplement 1) 498;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oncology: Basic, Translational & Therapy

  • Analysis of the 131I therapy in the young and adolescent patients with differentiated thyroid carcinoma
  • Volume changes in functional volumes of absorbed dose calculation to the kidneys and spleen in patients with neuroendocrine tumours receiving 177Lu-Octreotate therapy
  • Optimizing and Validating Reduced PET Volume Overlap in 18F-FDG Oncology Wholebody PET/CT to Improve Speed and Patient Comfort
Show more Oncology: Basic, Translational & Therapy

Radiopharmaceutical Therapy: Radioimmunotherapy

  • Anti-CD45 monoclonal antibody (MAb) dose optimization for astatine-211 (211At)-radioimmunotherapy (RIT) of relapsed non-Hodgkin lymphoma (NHL) in a canine model
  • Internal radiotherapy of 188Re-IDA-D-[c(RGDfK)]2 in combination with bevacizumab or temozolomide in U87-MG tumor-bearing mice
  • Anti-PSMA labeled liposomes loaded with Actinium-225 for potential antivascular alpha-radiotherapy
Show more Radiopharmaceutical Therapy: Radioimmunotherapy

Similar Articles

SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire